Seattle Genetics, Inc. (SGEN)
(Delayed Data from NSDQ)
$67.25 USD
+0.33 (0.49%)
Updated May 3, 2019 04:00 PM ET
After-Market: $67.27 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$67.25 USD
+0.33 (0.49%)
Updated May 3, 2019 04:00 PM ET
After-Market: $67.27 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Why Earnings Season Could Be Great for Seagen (SGEN)
by Zacks Equity Research
Seagen (SGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Exelixis (EXEL) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on pipeline and guidance updates when Exelixis (EXEL) reports fourth-quarter 2020 results.
What's in Store for AstraZeneca (AZN) This Earnings Season?
by Zacks Equity Research
AstraZeneca's (AZN) fourth-quarter results are expected to reflect the impact of new drug sales. However, coronavirus-led disruption is likely to have hurt sales.
CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On CRISPR Therapeutics' (CRSP) fourth-quarter earnings call, investor focus will be on the company's progress with the development of its lead gene-editing candidate, CTX001.
Incyte (INCY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors are likely to focus on pipeline updates besides top and bottom-line numbers when Incyte (INCY) reports fourth-quarter 2020 results.
Genmab (GMAB) Begins Phase III Study on Cervical Cancer Drug
by Zacks Equity Research
Genmab (GMAB) starts the global phase III innovaTV 301 study evaluating tisotumab vedotin versus chemotherapy for treating recurrent/metastatic cervical cancer.
Seagen (SGEN) Gets Positive CHMP Opinion for Breast Cancer Drug
by Zacks Equity Research
Seagen (SGEN) gets a positive opinion from the CHMP, recommending the approval of Tukysa for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer.
Seagens (SGEN) Q3 Earnings Rise Y/Y, Adcetris Sales View Cut
by Zacks Equity Research
Seagen's (SGEN) bottom line grows year over year in Q3 while revenues beat estimates. The company lowers the sales guidance for its lead product Adcetris.
Seattle Genetics (SGEN) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Seattle Genetics (SGEN) delivered earnings and revenue surprises of 4475.00% and 166.81%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Seattle Genetics (SGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Seattle Genetics (SGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merck (MRK) to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the sales numbers of Merck's (MRK) blockbuster oncology medicine, Keytruda.
5 Big Pharma/Biotech Stocks Set to Trump Q3 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks including Glaxo (GSK) and Merck (MRK) that are poised to beat on earnings for the third quarter.
Seagen Posts Upbeat Top-Line Data From EV-201 Study on Padcev
by Zacks Equity Research
Seagen (SGEN) and partner Astellas Pharma post favorable top-line results from the second cohort of the phase II EV-201 study on Padcev to treat advanced or metastatic urothelial cancer. Stock rises.
Merck Banks on Keytruda, Pipeline & Deals Amid Generic Woes
by Zacks Equity Research
Keytruda, approved for several types of cancer, alone accounts for more than 25% of Merck's (MRK) pharmaceutical sales Animal health and vaccine products remain core growth drivers.
Seattle Genetics' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Seattle Genetics.
Biotech Stock Roundup: Bristol-Myers' Updates, VCNX's Disappointing Data & More
by Zacks Equity Research
The biotech sector remains in focus with regulatory and other pipeline updates.
Seattle Genetics' Padcev Study Aids Urothelial Cancer Survival
by Zacks Equity Research
Seattle Genetics' (SGEN) phase III EV-301 study on Padcev meets the main goal of overall survival compared to chemotherapy in patients previously treated for locally advanced/metastatic urothelial cancer.
Pharma Stock Roundup: AZN, LLY & PFE's Coronavirus Updates, MRK's New Cancer Deals
by Kinjel Shah
AstraZeneca (AZN) resumes its coronavirus vaccine study in the United Kingdom. Merck (MRK) inks two oncology deals with Seattle Genetics.
Biotech Stock Roundup: GILD to Buy IMMU, SGEN Collaborates With Merck & More
by Zacks Equity Research
The biotech sector remains in focus with regulatory and other pipeline updates.
Seattle Genetics Up on Two New Oncology Deals With Merck
by Zacks Equity Research
Seattle Genetics (SGEN) strikes a couple of deals with Merck to co-develop ladiratuzumab vedotin for breast cancer and other solid tumors. Also, Merck will market the company's Tukysa in some places.
Merck Buys Rights to Co-Develop Seattle Genetics ADC Drug
by Zacks Equity Research
Merck (MRK) buys rights to co-develop/co-commercialize Seattle Genetics' ladiratuzumab vedotin. It acquires exclusive license to commercialize Tukysa for HER2-positive cancers in Asia, the Middle East and Latin America
Stock Market News for Sep 15, 2020
by Zacks Equity Research
U.S. stock markets closed higher on Monday reversing some of the losses of the last week.
M&A Activities Intensify in Pharma Industry
by Zacks Equity Research
M&A Activities Intensify in Pharma Industry.
No Econ Data, but Big Biopharma News
by Mark Vickery
Merck, Gilead and Lilly make progress on an otherwise slow news day.
Seattle Genetics (SGEN) Down 10.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.